USANA Health Sciences, Inc. (NYSE:USNA – Get Free Report) reached a new 52-week low during trading on Tuesday . The stock traded as low as $34.59 and last traded at $34.86, with a volume of 11798 shares. The stock had previously closed at $35.05.
Analysts Set New Price Targets
USNA has been the topic of a number of recent analyst reports. DA Davidson dropped their price objective on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a research report on Wednesday. StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th.
View Our Latest Research Report on USNA
USANA Health Sciences Stock Performance
USANA Health Sciences (NYSE:USNA – Get Free Report) last issued its quarterly earnings data on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.80%. The business had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. During the same quarter in the previous year, the firm earned $0.59 EPS. Research analysts anticipate that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current year.
Insiders Place Their Bets
In other news, insider Paul A. Jones sold 6,266 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Gilbert A. Fuller sold 674 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total transaction of $26,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul A. Jones sold 6,266 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. Insiders have sold a total of 7,940 shares of company stock valued at $311,670 over the last quarter. Company insiders own 0.33% of the company’s stock.
Institutional Investors Weigh In On USANA Health Sciences
Several large investors have recently modified their holdings of the stock. BOKF NA raised its position in USANA Health Sciences by 274.5% during the 1st quarter. BOKF NA now owns 2,771 shares of the company’s stock worth $133,000 after buying an additional 2,031 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of USANA Health Sciences by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after acquiring an additional 494 shares during the period. Exchange Traded Concepts LLC raised its holdings in USANA Health Sciences by 4.4% during the third quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock worth $292,000 after purchasing an additional 322 shares in the last quarter. SG Americas Securities LLC acquired a new stake in USANA Health Sciences in the second quarter valued at about $340,000. Finally, DGS Capital Management LLC boosted its holdings in USANA Health Sciences by 61.8% in the 1st quarter. DGS Capital Management LLC now owns 7,258 shares of the company’s stock valued at $352,000 after purchasing an additional 2,773 shares in the last quarter. Hedge funds and other institutional investors own 54.25% of the company’s stock.
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Recommended Stories
- Five stocks we like better than USANA Health Sciences
- Health Care Stocks Explained: Why You Might Want to Invest
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.